Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.60 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714012 | 0.92 | FOLH1 (0.62) | FOLH1CA2MAPK1NAALAD2FDPS | |
| SCHEMBL15068278 | 0.92 | FOLH1 (0.62) | FOLH1CA2MAPK1NAALAD2FDPS | |
| SCHEMBL9714134 | 0.92 | FOLH1 (0.62) | FOLH1CA2MAPK1NAALAD2FDPS | |
| SCHEMBL5057870 | 0.88 | FOLH1 (0.64) | FOLH1NAALAD2FDPSSLC1A3SLC1A2 | |
| SCHEMBL27507233 | 0.83 | CA2 (0.50) | FOLH1CA2MAPK1NAALAD2FDPS | |
| 2-Ethylhexanoic Acid SCHEMBL3655140 | 0.82 | CA2 (0.83) | FOLH1CA2MAPK1FDPSSLC1A3 | |
| SCHEMBL1304145 | 0.81 | FOLH1 (0.64) | FOLH1CA2MAPK1NAALAD2SLC1A3 | |
| SCHEMBL9697381 | 0.80 | SLC1A2 (0.53) | FOLH1CA2MAPK1SLC1A3SLC1A2 | |
| SCHEMBL593706 | 0.80 | CA2 (0.81) | FOLH1CA2MAPK1SLC1A3SLC1A2 | |
| SCHEMBL12145031 | 0.80 | FOLH1 (1.00) | FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-6054444-A | INHIBIT N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-25 | — | — | US | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-9279813-B2 | Ex vivo flow cytometry method and device | PURDUE RESEARCH FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140234866-A1 | EX VIVO FLOW CYTOMETRY METHOD AND DEVICE | PURDUE RESEARCH FOUNDATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0266978-A2 | Novel antibacterial agents and potentiators of carbapenem antibiotics | MERCK & CO. INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4351796-A | Method for scale control | CIBA-GEIGY CORPORATION (US) | 1982-09-28 | — | — | US | disclosed |
| EP-0008640-B1 | METHOD FOR THE REMOVAL OF HYDROGEN SULFIDE FROM GASES OR LIQUID HYDROCARBONS AND GASES OR LIQUID HYDROCARBONS THUS PURIFIED | CIBA-GEIGY AG (CH) | 1981-09-16 | — | — | EP | disclosed |
| US-4251492-A | REMOVAL OF HYDROGEN SULFIDE FROM GASES OR LIQUID HYDROCARBONS USING A PHOSPHONIC ACID COMPOUND SEQUESTERING AGENT | CIBA-GEIGY CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| EP-0008640-A1 | Method for the removal of hydrogen sulfide from gases or liquid hydrocarbons and gases or liquid hydrocarbons thus purified | CIBA-GEIGY AG (CH) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | FOLH1 56/4885CA2 382/4885MAPK1 4166/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885CA2 267/4885MAPK1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.